BIOA-B Stock Analysis: BioArctic (publ) | ST
Biotechnology | ST, Sweden | Market Cap: 27.221m SEK | 12M Return: 46.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 28.9M
Qual. Beats: 1
Rev. Trend: 57.6%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 8.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BioArctic AB (publ) is a Swedish biotechnology company that develops biological drugs, particularly antibody-based therapies, for central nervous system (CNS) disorders. Founded in 2000 and headquartered in Stockholm, the company targets neurodegenerative diseases with high unmet medical needs, including Alzheimers disease, Parkinsons disease, and ALS.
Its lead product, Lecanemab, is offered for intravenous treatment, with a subcutaneous formulation currently in registration. The pipeline also includes lecanemab in Phase 3 trials for presymptomatic Alzheimers treatment, Exidavnemab in Phase 2, and several preclinical and research-stage candidates such as BAN2803, ND3014, BAN2802, ND-BT8825, HD-BT4801, GD-BT6822, ND-BT3814, and PD-BT2238.
Operating as a clinical-stage biotech, BioArctic works within a sector defined by long R&D timelines, capital-intensive development, and a typical reliance on partnerships or licensing agreements with larger pharmaceutical companies for late-stage trials and commercialization.
- Lecanemab royalties from Eisai drive revenue growth
- Subcutaneous Lecanemab approval expands Alzheimers market access
- Eli Lillys Kisunla competition pressures Lecanemab share
| Net Income: 213.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.47 > 0.02 and ΔFCF/TA 55.73 > 1.0 |
| NWC/Revenue: 191.7% < 20% (prev 123.7%; Δ 68.08% < -1%) |
| CFO/TA 0.47 > 3% & CFO 1.25b > Net Income 213.2m |
| Net Debt (-1.99b) to EBITDA (411.1m): -4.85 < 3 |
| Current Ratio: 6.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.9m) vs 12m ago 0.31% < -2% |
| Gross Margin: 94.13% > 18% (prev 97.61%; Δ -3.48% > 0.5%) |
| Asset Turnover: 47.77% > 50% (prev 71.47%; Δ -23.70% > 0%) |
| Interest Coverage Ratio: 16.46 > 6 (EBIT TTM 398.4m / Interest Expense TTM 24.2m) |
| A: 0.82 (Total Current Assets 2.60b - Total Current Liabilities 397.1m) / Total Assets 2.68b |
| B: 0.50 (Retained Earnings 1.35b / Total Assets 2.68b) |
| C: 0.17 (EBIT TTM 398.4m / Avg Total Assets 2.40b) |
| D: 4.57 (Book Value of Equity 2.20b / Total Liabilities 481.2m) |
| Altman-Z'' = 12.94 = AAA |
As of July 28, 2026, the stock is trading at SEK 315.80 with a total of 86,457 shares traded. Over the past week, the price has changed by +5.97%, over one month by -2.53%, over three months by -2.25% and over the past year by +46.66%.
Current recommended Stop Loss: 296.20 (which is 6.2% or 1.8 ATR below the current price).
BioArctic (publ) has no consensus analysts rating.
P/E Trailing = 129.4515
P/E Forward = 20.7469
P/S = 23.7303
P/B = 12.4325
Revenue TTM = 1.15b SEK
EBIT TTM = 398.4m SEK
EBITDA TTM = 411.1m SEK
Long Term Debt = 28.3m SEK (from longTermDebtTotal, last fiscal year)
Short Term Debt = 15.7m SEK (from shortTermDebt, last quarter)
Debt = 40.7m SEK (from shortLongTermDebtTotal, last quarter) (leases 40.7m already included)
Net Debt = -1.99b SEK (calculated: Debt 40.7m - CCE 2.03b)
Enterprise Value = 25.2b SEK (27.2b + Debt 40.7m - CCE 2.03b)
Interest Coverage Ratio = 16.46 (Ebit TTM 398.4m / Interest Expense TTM 24.2m)
EV/FCF = 20.13x (Enterprise Value 25.2b / FCF TTM 1.25b)
FCF Yield = 4.97% (FCF TTM 1.25b / Enterprise Value 25.2b)
FCF Margin = 109.3% (FCF TTM 1.25b / Revenue TTM 1.15b)
Net Margin = 18.59% (Net Income TTM 213.2m / Revenue TTM 1.15b)
Gross Margin = 94.13% ((Revenue TTM 1.15b - Cost of Revenue TTM 67.3m) / Revenue TTM)
Gross Margin QoQ = none% (prev 91.82%)
Tobins Q-Ratio = 9.42 (Enterprise Value 25.2b / Total Assets 2.68b)
Interest Expense / Debt = 59.40% (Interest Expense 24.2m / Debt 40.7m)
Taxrate = 48.46% (200.5m / 413.7m)
NOPAT = 205.3m (EBIT 398.4m * (1 - 48.46%))
Current Ratio = 6.54 (Total Current Assets 2.60b / Total Current Liabilities 397.1m)
Debt / Equity = 0.02 (Debt 40.7m / totalStockholderEquity, last quarter 2.20b)
Debt / EBITDA = -4.85 (Net Debt -1.99b / EBITDA 411.1m)
Debt / FCF = -1.59 (Net Debt -1.99b / FCF TTM 1.25b)
Total Stockholder Equity = 2.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.88% (Net Income 213.2m / Total Assets 2.68b)
RoE = 10.44% (Net Income TTM 213.2m / Total Stockholder Equity 2.04b)
RoCE = 19.24% (EBIT 398.4m / Capital Employed (Equity 2.04b + L.T.Debt 28.3m))
RoIC = 9.16% (NOPAT 205.3m / Invested Capital 2.24b)
WACC = 7.18% (E(27.2b)/V(27.3b) * Re(7.19%) + (debt cost/tax rate unavailable))
Discount Rate = 7.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 66.52 | Cagr: 0.28%
[DCF] Terminal Value 75.44% ; FCFF base≈1.25b ; Y1≈1.26b ; Y5≈1.33b
[DCF] Fair Price = 305.8 (EV 20.7b - Net Debt -1.99b = Equity 22.7b / Shares 74.3m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: 57.60 | Revenue CAGR: 76.92% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.34 | Chg30d=+57.59% | Revisions=+25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.09 | Chg30d=+74.29% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=3.00 | Chg30d=+416.67% | Revisions=+40% | GrowthEPS=-74.0% | GrowthRev=-36.2%
EPS next Year (2027-12-31): EPS=7.15 | Chg30d=-3.47% | Revisions=+0% | GrowthEPS=+138.5% | GrowthRev=+38.7%
[Analyst] Revisions Ratio: +22% (up=4, down=2)